Payment overview · 2025
General Payments
$728.79
46 reported records · 18 companies
Healthcare provider profile · identity verified
Brian J Davis, DO
Allopathic & Osteopathic Physicians|Family Medicine · MILLVILLE, NJ · NPI 1437199346
Verified facts
What the public records show
CMS Open Payments records show Brian J Davis, DO received $728.79 in general payments during 2025 across 46 reported records.
Novo Nordisk Inc accounted for 21.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Ozempic by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $154.35 | 21.2% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $103.02 | 14.1% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $84.56 | 11.6% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $54.15 | 7.4% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $44.73 | 6.1% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $36.78 | 5.0% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.14 | 4.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.99 | 4.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.95 | 4.0% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $23.23 | 3.2% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $20.00 | 2.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.66 | 2.7% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $17.76 | 2.4% | 1 | 2025 |
| ModernaTX, Inc. | Unresolved — no canonical attribution shown | $16.91 | 2.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.88 | 2.3% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.57 | 2.1% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.02 | 2.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.09 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $728.79 | 46 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $108.08 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $88.31 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $84.56 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $84.56 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $57.26 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $54.15 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $45.76 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $45.76 | 3 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $44.73 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $36.78 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $32.14 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $28.95 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $23.23 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.66 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $17.76 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.41 | 1 | 2025 |
Source payment records
|
|||||
| mResvia Normalized: mresvia |
Drug | ModernaTX, Inc. | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.88 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 56 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 82 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 45 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
45 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
82 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 945 | 260 |
| Omeprazole | Omeprazole | 538 | 128 |
| Lisinopril | Lisinopril | 507 | 135 |
| Levothyroxine Sodium | Levothyroxine Sodium | 485 | 125 |
| Amlodipine Besylate | Amlodipine Besylate | 468 | 141 |
| Metformin Hcl | Metformin Hcl | 417 | 112 |
| Gabapentin | Gabapentin | 378 | 85 |
| Alprazolam | Alprazolam | 374 | 78 |
| Escitalopram Oxalate | Escitalopram Oxalate | 317 | 80 |
| Furosemide | Furosemide | 300 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 290 | 70 |
| Simvastatin | Simvastatin | 267 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 258 | 69 |
| Glimepiride | Glimepiride | 255 | 67 |
| Zolpidem Tartrate | Zolpidem Tartrate | 231 | 47 |
| Losartan Potassium | Losartan Potassium | 223 | 68 |
| Metoprolol Tartrate | Metoprolol Tartrate | 218 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 214 | 73 |
| Trazodone Hcl | Trazodone Hcl | 213 | 57 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 193 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 187 | 54 |
| Pravastatin Sodium | Pravastatin Sodium | 179 | 38 |
| Carvedilol | Carvedilol | 178 | 38 |
| Eliquis | Apixaban | 167 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 160 | 40 |
| Montelukast Sodium | Montelukast Sodium | 157 | 39 |
| Potassium Chloride | Potassium Chloride | 150 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 132 | 34 |
| Famotidine | Famotidine | 130 | 30 |
| Xarelto | Rivaroxaban | 129 | 14 |
| Buspirone Hcl | Buspirone Hcl | 125 | 24 |
| Ibuprofen | Ibuprofen | 119 | 34 |
| Sertraline Hcl | Sertraline Hcl | 116 | 26 |
| Bupropion Xl | Bupropion Hcl | 112 | 26 |
| Allopurinol | Allopurinol | 110 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 107 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 103 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 101 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 100 | 27 |
| Januvia | Sitagliptin Phosphate | 97 | 25 |
| Azithromycin | Azithromycin | 96 | 85 |
| Fluticasone Propionate | Fluticasone Propionate | 95 | 32 |
| Mirtazapine | Mirtazapine | 93 | 22 |
| Lorazepam | Lorazepam | 90 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 89 | 19 |
| Atenolol | Atenolol | 85 | 23 |
| Pregabalin | Pregabalin | 84 | 13 |
| Mounjaro | Tirzepatide | 82 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 79 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 71 | 18 |
| Clonazepam | Clonazepam | 70 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 68 | 61 |
| Tizanidine Hcl | Tizanidine Hcl | 68 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 67 | 19 |
| Metformin Hcl Er | Metformin Hcl | 65 | 11 |
| Alendronate Sodium | Alendronate Sodium | 64 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 63 | suppressed |
| Ezetimibe | Ezetimibe | 62 | 17 |
| Repaglinide | Repaglinide | 62 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 59 | 13 |
| Risperidone | Risperidone | 59 | suppressed |
| Prednisone | Prednisone | 58 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 20 |
| Jardiance | Empagliflozin | 56 | 15 |
| Naproxen | Naproxen | 56 | 11 |
| Meclizine Hcl | Meclizine Hcl | 55 | 29 |
| Warfarin Sodium | Warfarin Sodium | 55 | suppressed |
| Celecoxib | Celecoxib | 54 | 14 |
| Irbesartan | Irbesartan | 53 | 11 |
| Meloxicam | Meloxicam | 53 | 16 |
| Memantine Hcl | Memantine Hcl | 53 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 49 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 39 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 43 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 43 | 13 |
| Aripiprazole | Aripiprazole | 42 | 15 |
| Baclofen | Baclofen | 41 | suppressed |
| Finasteride | Finasteride | 41 | suppressed |
| Ramipril | Ramipril | 41 | 11 |
| Donepezil Hcl | Donepezil Hcl | 40 | 12 |
| Ozempic | Semaglutide | 40 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 40 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 36 | suppressed |
| Entresto | Sacubitril/Valsartan | 36 | suppressed |
| Valsartan | Valsartan | 36 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 22 |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 18 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Glipizide | Glipizide | 31 | suppressed |
| Methylprednisolone | Methylprednisolone | 31 | 27 |
| Olanzapine | Olanzapine | 31 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 31 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Ketoconazole | Ketoconazole | 29 | 15 |
| Metoclopramide Hcl | Metoclopramide Hcl | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 28 | suppressed |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Carbamazepine | Carbamazepine | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Desoximetasone | Desoximetasone | 22 | 17 |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | 11 |
| Topiramate | Topiramate | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Indomethacin | Indomethacin | 21 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | suppressed |
| Cilostazol | Cilostazol | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 20 | 15 |
| Amoxicillin | Amoxicillin | 19 | 16 |
| Colchicine | Colchicine | 19 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Invokana | Canagliflozin | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 18 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Movantik | Naloxegol Oxalate | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | 14 |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Alyacen | Norethindrone-Ethin. Estradiol | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Entacapone | Entacapone | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Altace | Ramipril | 12 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $728.79 · 46 records | Novo Nordisk Inc | AIRSUPRA, Auvelity, Cologuard Collection Kit, FREESTYLE LIBRE 3, GEMTESA, INSPIRE, JARDIANCE, KRYSTEXXA, Korlym, MOUNJARO, Ozempic, QULIPTA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TZIELD, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND, ZORYVE, mResvia | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error